The weekly litigation news digest is live. Subscribe now

IP Verse

Injectable Flowable Composition Comprising Buprenorphine - EP2579874

The patent EP2579874 was granted to Indivior UK on Jan 10, 2018. The application was filed on Jun 6, 2011 under application number EP11728037A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2579874

INDIVIOR UK
Application Number
EP11728037A
Filing Date
Jun 6, 2011
Status
Opposition Rejected
Sep 9, 2022
Publication Date
Jan 10, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
TEVA PHARMACEUTICALSOct 10, 2018LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS4938763
DESCRIPTIONUS5278201
DESCRIPTIONUS5324519
DESCRIPTIONUS5702716
DESCRIPTIONUS5744153
DESCRIPTIONUS5990194
DESCRIPTIONUS6461631
DESCRIPTIONUS6565874
INTERNATIONAL-SEARCH-REPORTWO2004043432
INTERNATIONAL-SEARCH-REPORTWO2009091737
OPPOSITIONWO0024374
OPPOSITIONWO2008100532
OPPOSITIONWO2011154724

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents